| Ascl1 phospho-site mutations enhance neuronal conversion of adult cortical astrocytes in vivo H Ghazale, EJ Park, L Vasan, J Mester, F Saleh, A Trevisiol, D Zinyk, ... Frontiers in Neuroscience 16, 917071, 2022 | 11 | 2022 |
| Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis K Galetta, C Deshpande, BC Healy, B Glanz, M Ziehn, S Saxena, A Paul, ... Annals of Clinical and Translational Neurology 8 (3), 631-638, 2021 | 10 | 2021 |
| Clinical validation of a multi-protein, Serum-based assay for disease activity assessments in multiple sclerosis T Chitnis, J Foley, C Ionete, NK El Ayoubi, S Saxena, P Gaitan-Walsh, ... Clinical Immunology 253, 109688, 2023 | 5 | 2023 |
| Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes G Bose, BC Healy, S Saxena, F Saleh, A Paul, C Barro, HA Lokhande, ... Multiple Sclerosis and Related Disorders 74, 104695, 2023 | 5 | 2023 |
| Clinical validation study results of a multivariate proteomic serum based assay for disease activity assessments in multiple sclerosis T Chitnis, J Foley, C Ionete, N El Ayoubi, S Saxena, P Gaitan-Walsh, ... Age (Mean±SD) 41 (12.7), 42.5-13.5, 2021 | 3 | 2021 |
| Validation of two kinetic assays for the quantification of endotoxin in human serum C Barro, A Paul, F Saleh, T Chitnis, HL Weiner Frontiers in Neurology 12, 691683, 2021 | 2 | 2021 |
| NEUROG2 regulates a human-specific neurodevelopmental gene regulatory program V Chinchalongporn, L Vasan, F Saleh, D Zinyk, H Ghazale, AM Oproescu, ... bioRxiv, 2024.01. 11.575174, 2024 | 1 | 2024 |
| Serum NfL and GFAP biomarker analysis in early high versus low efficacy DMT paradigms for MS (P1-1. Virtual) VFM Ferreira, J Zurawski, BC Healy, S Saxena, A Paul, F Saleh, Y Liu, ... Neurology 98 (18 Supplement), 2022 | 1 | 2022 |
| Multivariate Proteomic MS Disease Activity Test Result Distributions Based on Disease Modifying Therapy Categories T Chitnis, J Foley, C Ionete, N El Ayoubi, S Saxena, P Gaitan-Walsh, ... Age (Mean±SD) 42, 13.0, 2022 | 1 | 2022 |
| Clinical validation study results of a multivariate proteomic serum based assay for disease activity assessments in MS T Chitnis, J Foley, C Ionete, N El Ayoubi, S Saxena, P Gaitan-Walsh, ... MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 510-511, 2021 | 1 | 2021 |
| Multivariate protein biomarker models more accurately predict multiple sclerosis MRI disease activity compared to serum levels of neurofilament light chain alone T Chitnis, H Yano, S Saxena, H Lokhande, N Sattarnezhad, MC Manieri, ... MULTIPLE SCLEROSIS JOURNAL 25, 731-731, 2019 | 1 | 2019 |
| Pten regulates endocytic trafficking of cell adhesion and Wnt signaling molecules to pattern the retina Y Touahri, J Hanna, N Tachibana, S Okawa, H Liu, LA David, T Olender, ... Cell Reports 43 (4), 2024 | | 2024 |
| Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity G Bose, BC Healy, S Saxena, F Saleh, BI Glanz, R Bakshi, HL Weiner, ... Neurology: Neuroimmunology & Neuroinflammation 10 (6), e200167, 2023 | | 2023 |
| Overcoming Neuronal Reprogramming Barriers as a Novel Therapeutic Strategy for ALS H Ghazale, E Park, L Vasan, F Saleh, D Zinyk, V Chinchalongporn, ... GLIA 71, E1126-E1126, 2023 | | 2023 |
| Serum GFAP and long-term outcomes in high efficacy versus low efficacy early treatment in multiple sclerosis VF Ferreira, J Zurawski, BC Healy, S Saxena, A Paul, F Saleh, Y Liu, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 355-355, 2022 | | 2022 |
| Serum NfL and GFAP biomarker analysis in early high versus low efficacy DMT paradigms for MS VM Ferreira, J Zurawski, B Healy, S Saxena, A Paul, F Saleh, Y Liu, ... EUROPEAN JOURNAL OF NEUROLOGY 29, 295-295, 2022 | | 2022 |
| Function of miRNA profiled in Teriflunomide treated multiple sclerosis (MS) patients (P4-4.003) F Saleh, A Paul, T Chitnis, H Weiner Neurology 98 (18 Supplement), 2022 | | 2022 |
| Early Levels of Neurofilament Light Chain and Glial Fibrillary Acidic Protein Improve Prediction of MS Outcomes (S19. 002) G Bose, B Healy, S Saxena, F Saleh, A Paul, M Sotiropoulos, H Lokhande, ... Neurology 98 (18 Supplement), 2022 | | 2022 |
| Estimation of Disability Status from Blood Serum Protein Concentrations T Chitnis, J Foley, C Ionete, N El Ayoubi, S Saxena, P Gaitan-Walsh, ... MULTIPLE SCLEROSIS JOURNAL 28 (1_ SUPPL), 32-32, 2022 | | 2022 |
| Serum Neurofilament Light and Glial Fibrillary Acidic Protein Levels at MS Onset and Follow-up Improve Predictive Models of 10-Year Outcomes G Bose, BC Healy, S Saxena, F Saleh, A Paul, C Barro, H Lokhande, ... MULTIPLE SCLEROSIS JOURNAL 28 (1_ SUPPL), 46-46, 2022 | | 2022 |
